Ann: Appendix 4C Quarterly Activity Report, page-84

This is my first post in almost a year (likemany, having seen a significant unrealised profit evaporate, the day the ARDStrial was stopped).

I went off into the wilderness to lick my wounds and contemplate what couldhave been.

I have however, maintained my holding and continue to read the MSBposts on HC and YH.

I now have a question that I’m hoping oneof the resident experts can answer.

When I initially read the 4C document on Friday Morning one word stood out “appropriateness”(see the extract below).

Does this mean that SI/MSB are questioning the need or relevance of potencyassays relating to Rem-L and how does this relate to the what the FDA haveasked regarding “potency assays”?

I looked up the definition of “potency assays” (the quantitative measure of biologicalactivity)to see if thiswould help answer my question (it didn't).

Have I misunderstood/misinterpreted the statement?